Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPLS adjuvant

Skeiky, Yasir A. W.; Coler, Rhea N.; Brannon, Mark; Stromberg, Erika; Greeson, Kay; Crane, Ryan; Campos-Neto, Antônio; Reed, Steven G.

doi:10.1016/s0264-410x(02)00302-x

Cited by 156 publications

(104 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Here, we began the evaluation of a mixture of the recombinant antigens TSA, LmSTI1 and LeIF as candidate vaccine for VL. These antigens have been successfully shown to induce an excellent protection against cutaneous leishmaniasis in the murine and non-human primate models [9,30,41] and currently are been tested in Phase I/II human vaccine clinical trials. Because these antigens are highly conserved among the Leishmania species and are expressed in both the amastigote and the promastigote forms of the parasites [39,40,46], they could be useful as a component of a panLeishmania vaccine [20].…”

Section: Discussionmentioning

confidence: 99%

“…Despite the possibility that a single antigen could by itself induce good protection, we chose to test a mixture of these three proteins because a cocktail of several antigens is conceivably a better vaccine for both prophylactic and therapeutic applications because a vaccine containing a broader range of protective epitopes is unlikely to suffer from MHC related unresponsiveness in a heterogeneous population. Moreover, the use of several antigens can potentially decrease the effects of the selective pressure on the parasite to modify multiple genes [41].…”

Section: Discussionmentioning

confidence: 99%

“…The dogs were also treated with anti-helminthic drugs (Endal Plus ® , Schering Plough, Brazil) and with anti-ectoparasites (Frontline ® , Merial Inc., USA), and were quarantined for approximately four weeks before beginning the vaccine trial. One group received a mixture of TSA, LmSTI1 and LeIF (10 µg each) with AdjuPrime ® (1 mg, Pierce Chemical, USA) as the adjuvant; a second group was vaccinated with TSA, LmSTI1 and LeIF (10 µg each) and monophosphoryl lipid A (MPL) plus squalene (MPL-SE ® ) (50 µg, Corixa Co., USA) [41] …”

Section: Animals and Immunizationsmentioning

confidence: 99%

“…Three highly conserved antigens among the Leishmania genus, TSA, LmSTI1 and LeIF, have been shown to induce excellent protection in both the murine and non-human primate models of the human disease [8,41]. Moreover, vaccination with plasmid DNA encoding these antigens conferred protection against L. major infection in BALB/c [9,30,31].…”

Section: Introductionmentioning

confidence: 99%

“…Moreover, vaccination with plasmid DNA encoding these antigens conferred protection against L. major infection in BALB/c [9,30,31]. A single recombinant polyprotein comprising the sequences of all three recombinant proteins has been produced and tested in BALB/c mice against L. major infection formulated with MPL-SE ® (Monophosphoryl Lipid A plus squalene) and the results showed excellent protective immunity against the challenge with virulent parasites [41]. This polyprotein is currently being tested in phase I/II human clinical trials against cutaneous leishmaniasis.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis

et al. 2005

View full text Add to dashboard Cite

-Control of canine visceral leishmaniasis (VL) remains a difficult and serious problem mostly because there is no reliable and effective vaccine available to prevent this disease. A mixture of three recombinant leishmanial antigens (TSA, LeIF and LmSTI1) encoded by three genes highly conserved in the Leishmania genus have been shown to induce excellent protection against infection in both murine and simian models of cutaneous leishmaniasis. A human clinical trial with these antigens is currently underway. Because of the high degree of conservation, these antigens might be useful vaccine candidates for VL as well. In the present study, using the dog model of the visceral disease, we evaluated the immunogenicity of these three antigens formulated with two different adjuvants, MPL-SE ® and AdjuPrime ® . The results were compared with a whole parasite vaccine formulated with BCG as the adjuvant. In order to investigate if sensitization with the recombinant antigens would result in recognition of the corresponding native parasite antigens upon infection, the animals were exposed for four weeks after the termination of the immunization protocol with the recombinant antigens to a low number of L. chagasi promastigotes, an etiological agent of VL. Immune response was evaluated by quantitative ELISA in the animal sera before and after exposure

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Animals and Immunizationsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis

et al. 2005

View full text Add to dashboard Cite

show abstract

Current Approaches to the Development of a Vaccine Against Leishmaniasis

Goto¹,

Reed²

2012

Immunity to Parasitic Infection

View full text Add to dashboard Cite

Development of the Antileishmanial Vaccine

et al. 2021

View full text Add to dashboard Cite

Search for an efficacious antileishmanial vaccine has led to clinical trials of numerous vaccine candidates in the past few decades. As no promising candidate has emerged from these studies, novel vaccine modalities and vaccine assessment techniques are still emerging for antileishmanial vaccine development. Briefly, this chapter discusses: (a) history and timeline of antileishmanial vaccine development; (b) techniques utilized for developing whole-parasite and subunit-based antileishmanial vaccine formulations, and (c) immunogenicity and post-challenge protective efficacy assessment of vaccine candidates.

show abstract

Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPLS adjuvant

Cited by 156 publications

References 35 publications

Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis

Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis

Current Approaches to the Development of a Vaccine Against Leishmaniasis

Development of the Antileishmanial Vaccine

Contact Info

Product

Resources

About